The objective of this study, published in the International Journal of Chronic Obstructive Pulmonary Disease, was to describe the trends in pharmacologic treatment for patients newly diagnosed with chronic obstructive pulmonary disease (COPD) in Alberta, Canada.
- Chronic Diseases / Disorders
- Community Health Centres
- Fetal Alcohol Spectrum Disorder (FASD)
- Health Economics / Healthcare Costs
- Health Measurement Tools
- Health Policy
- Health Technology Assessment
- Healthcare Services
- Infectious Diseases
- Maternal and Child Health
- Mental Health
- Nurse Practitioners
- Primary Care
- Quality of Life
The outcome of IHE initiatives is providing better information for developing health policy and best medical practices. IHE disseminates information in many ways. In addition to publications in peer-reviewed journals, IHE produces books and a variety of reports synthesizing information in a particular field.
If you cannot find the publication or report you are seeking, please contact us at [email protected]. Thank you!
Refine your search by clicking filters to the left.
Results for: Pharmaceuticals
This study, published in PharmacoEconomics – Open, reports exploratory analysis of the provincial and nationwide costs of industry-sponsored drug clinical trials (CTs) in Canada. The costs of industry-sponsored drug CTs completed in 2016 were Can$2.1 billion. In addition to the creation of knowledge, these trials play an important role in alleviating the healthcare cost burden…
Ce rapport fournit un résumé d’un atelier de sprint sur la conception de données probantes du monde réel (DPMR) qui a eu lieu le 21 octobre 2018 à Toronto, en Ontario. L’atelier a été conçu et offert dans le cadre d’un partenariat entre l’Agence canadienne des médicaments et des technologies…
This report provides a summary of a real-world evidence (RWE) design sprint workshop that took place on October 21, 2018 in Toronto, Ontario. The workshop was developed and delivered as a joint partnership between the Canadian Agency for Drugs and Technologies in Health (CADTH); Canadian Association for Population Therapeutics (CAPT), Health Canada, and the Institute of Health…
This brief outlines some perspectives from the Institute of Health Economics (IHE) based on what we have heard from government, public agencies, and industry, and seeks to summarize the key areas where further clarification and deliberation could be helpful.
As the Federal Government contemplates introducing an element of value-based pricing to the pharmaceutical industry regulatory framework, this report provides an overview of key theoretical and empirical material, to support informed engagement by all stakeholders in this important debate.
Purpose: In pharmaceutical clinical trials, industrial sponsors pay for study drugs and related healthcare services. We conducted a study to determine industry’s economic contribution of these trials to the Alberta healthcare system. Authors and Affiliations: Dat T. Tran1,2; Ilke Akpinar2 ; Richard N. Fedorak3 ; Egon Jonsson2 ; John R. Mackey4 ; Lawrence Richer5 ; Philip…
This report provides a summary of the IHE Biosimilars Forum engagement exercise that took place on April 23, 2017 in Ottawa, Ontario. The intent of the forum was to identify: options to categorize and consider biosimilars; a process to engage stakeholders to identify place in therapy and further evidence development that may be required; and an approach to knowledge exchange that…
PDF of a PowerPoint presentation by Dr. Asbjørn Mack, Chief Negotiator Pharamaceuticals, LIS, Norway. 6 Oct 2016 – IHE Biosimilars Forum
PDF of a PowerPoint presentation by Mr. Murray Aitken, Senior VP and Executive Director, IMS Institute for Healthcare Informatics. 6 Oct 2016 – IHE Biosimilars Forum
BACKGROUND: The use of a restrictive formulary, with placement determined through a drug-reimbursement decision-making process, is one approach to managing drug expenditures.
Abstract: The cost of drug development is commonly cited between US$800 and US$1.8 billion. A similar statistic for vaccines is yet to be estimated, and it is unclear whether the cost of vaccines is similar to drug development. Financial and regulatory policy significantly impacts the extent and cost of pharmaceutical development, and as such it is important that…
Objectives: To estimate the monetary benefits of ramipril and its distribution over time among four beneficiaries in Canada: the drug developing manufacturer, generic manufacturers, the healthcare sector and employment sectors.
This report is an analysis of the theoretical basis for value-based pricing, relevant international developments, and areas for improvement within Canada’s current patented drug pricing system. This report intends to inform future policy research, advice, and Canadian drug policy discussions regarding the feasibility and implementation of value-based pricing approaches.
Background: The benefits of pharmaceutical innovations are widely diffused; they accrue to the healthcare providers, patients, employers, and manufacturers. We estimate the societal monetary benefits of simvastatin in Canada and its distribution among different beneficiaries overtime.
Alberta Heritage Foundation for Medical Research (AHFMR) Information Paper #24. The objective of this paper is to present the current evidence on the efficacy/effectiveness and safety of celeoxib (Celebrex®) for the treatment of pain in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Information Specialist: Seana Collins NOTE: In 2006 the Alberta Heritage Foundation…